Sweden
· Delayed Price · Currency is SEK · Price in NOKGenetic Analysis AS Statistics
Total Valuation
Genetic Analysis AS has a market cap or net worth of SEK 36.90 million. The enterprise value is 34.53 million.
| Market Cap | 36.90M |
| Enterprise Value | 34.53M |
Important Dates
The next estimated earnings date is Friday, November 1, 2024.
| Earnings Date | Nov 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genetic Analysis AS has 49.38 million shares outstanding. The number of shares has increased by 87.99% in one year.
| Shares Outstanding | 49.38M |
| Shares Change (YoY) | +87.99% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.32% |
| Owned by Institutions (%) | 12.75% |
| Float | 22.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.76 |
| PB Ratio | 1.25 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.61 |
| EV / Sales | 1.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.92 |
Financial Position
The company has a current ratio of 1.79, with a Debt / Equity ratio of 17.10.
| Current Ratio | 1.79 |
| Quick Ratio | 1.69 |
| Debt / Equity | 17.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.25 |
| Interest Coverage | -33.69 |
Financial Efficiency
Return on equity (ROE) is -74.61% and return on invested capital (ROIC) is -38.84%.
| Return on Equity (ROE) | -74.61% |
| Return on Assets (ROA) | -28.35% |
| Return on Capital (ROIC) | -38.84% |
| Revenue Per Employee | 986,343 |
| Profits Per Employee | -1.02M |
| Employee Count | 21 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 2.87 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.35% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -34.35% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 0.77 |
| Relative Strength Index (RSI) | 42.54 |
| Average Volume (20 Days) | 16,638 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genetic Analysis AS had revenue of SEK 20.71 million and -21.49 million in losses. Loss per share was -0.46.
| Revenue | 20.71M |
| Gross Profit | 16.27M |
| Operating Income | -21.26M |
| Pretax Income | -21.49M |
| Net Income | -21.49M |
| EBITDA | -21.42M |
| EBIT | -21.26M |
| Loss Per Share | -0.46 |
Balance Sheet
The company has 6.93 million in cash and 4.47 million in debt, giving a net cash position of 2.46 million or 0.05 per share.
| Cash & Cash Equivalents | 6.93M |
| Total Debt | 4.47M |
| Net Cash | 2.46M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 26.17M |
| Book Value Per Share | 0.62 |
| Working Capital | 8.96M |
Cash Flow
In the last 12 months, operating cash flow was -18.01 million and capital expenditures 681, giving a free cash flow of -18.01 million.
| Operating Cash Flow | -18.01M |
| Capital Expenditures | 681 |
| Free Cash Flow | -18.01M |
| FCF Per Share | -0.36 |
Margins
Gross margin is 78.54%, with operating and profit margins of -102.66% and -103.74%.
| Gross Margin | 78.54% |
| Operating Margin | -102.66% |
| Pretax Margin | -103.74% |
| Profit Margin | -103.74% |
| EBITDA Margin | -103.43% |
| EBIT Margin | -102.66% |
| FCF Margin | -86.96% |
Dividends & Yields
Genetic Analysis AS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -87.99% |
| Shareholder Yield | -87.99% |
| Earnings Yield | -61.27% |
| FCF Yield | -48.82% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |